Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

NCT05642078 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2550

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Influenza

Interventions

BIOLOGICAL: Investigational Vaccine(0.25ml/vial)
BIOLOGICAL: Investigational Vaccine(0.5ml/vial)
BIOLOGICAL: Active compared Vaccine

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.